Biotheryx BTX-9341 Phase 1A Results to Be Presented at ESMO Breast Cancer Congress 2026

Key Takeaways

• Biotheryx will present Phase 1A dose escalation study data for BTX-9341, a first-in-class CDK4/6 protein degrader
• The study targets HR+/HER2- breast cancer patients who previously received CDK4/6 inhibitor therapy
• Results will be showcased at the 2026 European Society for Medical Oncology Breast Cancer Annual Congress

---

SAN DIEGO - Biotheryx, Inc. announced today that clinical data from its Phase 1A dose escalation study of BTX-9341 will be presented at the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.

Novel CDK4/6 Degrader Shows Promise

BTX-9341 represents a first-in-class protein degrader specifically targeting CDK4/6 proteins. The investigational drug is being evaluated in combination with fulvestrant for treating hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer in patients who have previously received CDK4/6 inhibitor therapy in advanced and/or metastatic settings.

This patient population represents a significant unmet medical need, as resistance to CDK4/6 inhibitors remains a major challenge in HR+/HER2- breast cancer treatment. Traditional CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib have transformed treatment outcomes, but acquired resistance limits their long-term effectiveness.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Protein Degradation Technology Advantage

Unlike conventional CDK4/6 inhibitors that temporarily block protein function, BTX-9341 employs proteolysis-targeting chimera (PROTAC) technology to permanently degrade target proteins. This mechanism may overcome resistance patterns seen with traditional inhibitors and provide renewed treatment options for patients with progressive disease.

The biopharmaceutical company focuses on discovering and developing first-in-class protein degraders for cancer and inflammatory diseases, positioning itself at the forefront of this emerging therapeutic approach.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Future Outlook

The HR+/HER2- breast cancer segment represents approximately 70% of all breast cancer cases, making it the largest subtype. With growing resistance to current CDK4/6 inhibitors, novel approaches like protein degradation could capture significant market share in the post-CDK4/6 inhibitor setting.

The upcoming ESMO presentation will provide crucial insights into BTX-9341’s safety profile, dosing parameters, and preliminary efficacy signals, informing the drug’s development trajectory and potential advancement to Phase 1B or Phase 2 studies.

---

Frequently Asked Questions

What makes BTX-9341 different from existing CDK4/6 inhibitors?

BTX-9341 is a protein degrader that permanently destroys CDK4/6 proteins rather than temporarily blocking them, potentially overcoming resistance to traditional CDK4/6 inhibitors like palbociclib and ribociclib.

When will BTX-9341 be available for patients?

BTX-9341 is currently in Phase 1A trials and is years away from potential approval. The drug must complete Phase 1, Phase 2, and Phase 3 studies before seeking regulatory approval, typically taking 5-10 years.

Which patients could benefit from BTX-9341?

The current study targets HR+/HER2- breast cancer patients who have previously received CDK4/6 inhibitor therapy and experienced disease progression, representing a population with limited treatment options.

Related coverage

• Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights
• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
• Circulating Biomarkers: Additional Evidence Supporting Their Clinical Use in Breast Cancer